Research programme: spinal muscular atrophy therapeutics - Paratek Pharmaceuticals/Families of SMA

Drug Profile

Research programme: spinal muscular atrophy therapeutics - Paratek Pharmaceuticals/Families of SMA

Alternative Names: PKT SMA 01; PTK-SMA-01

Latest Information Update: 24 Jun 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Families of SMA; Paratek Pharmaceuticals
  • Class Small molecules; Tetracyclines
  • Mechanism of Action Survival of motor neuron 1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Spinal muscular atrophy

Most Recent Events

  • 17 Jun 2008 Families of Spinal Muscular Atrophy and Paratek Pharmaceuticals have extended their research collaboration for another year
  • 03 Apr 2007 Families of Spinal Muscular Atrophy and Paratek Pharmaceuticals have extended their research collaboration
  • 24 May 2006 Preclinical trials in Spinal muscular atrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top